Teva and Takeda Settle Litigation

Teva Pharmaceutical Industries Ltd. TEVA announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to settle patent litigation related to Teva's generic versions of Takeda's ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) for the United States. Takeda has granted Teva a license to market an authorized generic version of ACTOS in the U.S. beginning on August 17, 2012, or earlier under certain circumstances. Furthermore, Takeda has granted Teva a license to market an authorized generic version of ACTOplus met in the U.S. beginning on December 14, 2012, or earlier under certain circumstances.